3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
104
Lymphoma, Large B-Cell, Diffuse
81
Leukemia, Myeloid, Acute
75
Multiple Myeloma
71
Breast Neoplasms
70
Lymphoma, Non-Hodgkin
62
Lymphoma
62
Leukemia, Lymphocytic, Chronic, B-Cell
53
Burkitt Lymphoma
53
Recurrence
51
Myelodysplastic Syndromes
50
Lymphoma, Follicular
49
Lymphoma, B-Cell
48
Leukemia
43
Triple Negative Breast Neoplasms
40
Lymphoma, Mantle-Cell
38
Neoplasms
37
Melanoma
34
Hodgkin Disease
34
Lymphoma, B-Cell, Marginal Zone
32
Hematologic Neoplasms
31
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
29
Neuroblastoma
28
Ovarian Neoplasms
26
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
22
Neoplasm Metastasis
22
Pancreatic Neoplasms
21
Leukemia, Biphenotypic, Acute
21
Sarcoma
18
Myeloproliferative Disorders
17
Interventions
Specimen Handling
9
Nivolumab
9
Ipilimumab
7
cabozantinib
6
CTLA-4 Antigen
6
pembrolizumab
5
Magnetic Resonance Spectroscopy
5
Biopsy
4
Axitinib
4
lenvatinib
2
fludarabine
2
Blood Specimen Collection
2
tivozanib
1
sodium-iodide symporter
1
sitravatinib
1
belzutifan
1
aldesleukin
1
Zoledronic Acid
1
Tissue Banks
1
Selenomethionine
1
Radiotherapy
1
Radiopharmaceuticals
1
Pluvicto
1
Nephrectomy
1
Metastasectomy
1
Inulin
1
Immunoglobulin G
1
Ibandronic Acid
1
Hyaluronoglucosaminidase
1
Everolimus
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Clear-cell metastatic renal cell carcinoma
×
Cyclophosphamide
×
1 year
×
Clear all
NCT04696731
2025-09-25
TRAVERSE
Allogene Therapeutics
Phase 1
Active not recruiting
120 enrolled